Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been given a consensus rating of “Moderate Buy” by the twelve research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $37.80.

A number of analysts have recently issued reports on RCUS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Friday, July 17th. HC Wainwright raised their price target on shares of Arcus Biosciences from $32.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Wedbush lifted their price objective on shares of Arcus Biosciences from $41.00 to $43.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Lifesci Capital began coverage on shares of Arcus Biosciences in a research report on Thursday, June 4th. They issued an “outperform” rating and a $46.00 price objective for the company. Finally, Wells Fargo & Company lifted their target price on Arcus Biosciences from $23.00 to $26.00 and gave the company an “equal weight” rating in a research report on Thursday, August 6th.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, President Juan C. Jaen sold 48,502 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $30.05, for a total transaction of $1,457,485.10. Following the transaction, the president owned 842,307 shares of the company’s stock, valued at approximately $25,311,325.35. This trade represents a 5.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,827 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $30.00, for a total transaction of $84,810.00. Following the completion of the sale, the chief accounting officer owned 39,581 shares of the company’s stock, valued at approximately $1,187,430. This represents a 6.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 105,389 shares of company stock worth $3,060,164. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 10.0% during the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after purchasing an additional 359 shares during the period. Royal Bank of Canada boosted its holdings in Arcus Biosciences by 14.6% during the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock worth $102,000 after buying an additional 607 shares in the last quarter. Creative Planning grew its position in Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after buying an additional 771 shares during the period. Hantz Financial Services Inc. grew its position in Arcus Biosciences by 121.9% during the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after buying an additional 881 shares during the period. Finally, New York State Teachers Retirement System increased its holdings in Arcus Biosciences by 1.1% in the fourth quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock valued at $2,203,000 after buying an additional 1,000 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences Price Performance

Shares of RCUS stock opened at $30.91 on Friday. Arcus Biosciences has a 52-week low of $10.25 and a 52-week high of $31.74. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82. The firm has a market capitalization of $3.94 billion, a P/E ratio of -7.93 and a beta of 0.80. The stock has a 50 day moving average price of $28.91 and a 200 day moving average price of $24.99.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%.The company had revenue of $41.00 million for the quarter, compared to the consensus estimate of $21.98 million. The company’s revenue for the quarter was down 74.4% compared to the same quarter last year. As a group, sell-side analysts predict that Arcus Biosciences will post -3.6 earnings per share for the current year.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.